HES1 and prostate carcinoma: Notch signaling has been reported to become activated in prostate cancer cell lines exhibiting resistance to the clinically available AR inhibitor enzalutamide, as verified by the increased levels of cleaved NOTCH1, HES1 and c-MYC [70].